Evidence map›Paper›PMID 27376469›Full record

ArticleNature immunology2016

Activin A programs the differentiation of human TFH cells.

Michela Locci, Jennifer E Wu, Fortuna Arumemi, Zbigniew Mikulski, Carol Dahlberg, Andrew T Miller, Shane Crotty

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Nature immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 112 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 1 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Targeting T follicular helper cells for lifelong health.Nature reviews. Drug discovery · 2026
    Review
  4. Macrophage heterogeneity in human secondary lymphoid organs.Clinical science (London, England : 1979) · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. T follicular helper cells in primary immune regulatory disorders.The Journal of allergy and clinical immunology · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Michela LocciDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Jennifer E WuDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Fortuna ArumemiDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Zbigniew MikulskiMicroscopy Core Facility, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Carol DahlbergGenomics Institute of the Novartis Research Foundation, La Jolla, California, USA.
Andrew T MillerGenomics Institute of the Novartis Research Foundation, La Jolla, California, USA.
Shane CrottyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.ORCID 0000-0002-6484-6262
La Jolla Institute for Immunology · USGenomics Institute of the Novartis Research Foundation · USInternational AIDS Vaccine Initiative · US

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Role of Follicular T Helper Cells In Enhancing Humoral Immunity and ProtectionU19AI096187 · NIAID · EMORY UNIVERSITY · PI DERDEYN, CYNTHIA ANN · 2011 to 2015
$26.5M
Tfh and SAP and T cell help to B cellsR01AI072543 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROTTY, SHANE P · 2008 to 2018
$4.6M
FACSAria II Cell SorterS10RR027366 · NCRR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2011 to 2011
$514k
NIAID NIH HHS R01 AI072543NIAID NIH HHS U19 AI096187NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

Follicular helper T cells (TFH cells) are CD4(+) T cells specialized in helping B cells and are associated both with protective antibody responses and autoimmune diseases. The promise of targeting TFH cells therapeutically has been limited by fragmentary understanding of extrinsic signals that regulate the differentiation of human TFH cells. A screen of a human protein library identified activin A as a potent regulator of TFH cell differentiation. Activin A orchestrated the expression of multiple genes associated with the TFH program, independently or in concert with additional signals. TFH cell programming by activin A was antagonized by the cytokine IL-2. Activin A's ability to drive TFH cell differentiation in vitro was conserved in non-human primates but not in mice. Finally, activin-A-induced TFH programming was dependent on signaling via SMAD2 and SMAD3 and was blocked by pharmacological inhibitors.

Indexed as

ActivinsAnimalsBiological EvolutionCell DifferentiationCells, CulturedGene Expression RegulationGerminal CenterHumansInterleukin-2MiceMice, Inbred BALB CMice, Inbred C57BLPrimatesSignal TransductionSmad2 ProteinSmad3 Proteinactivin AActivinsInterleukin-2Smad2 ProteinSmad3 Protein

Identifiers

PMID27376469
PMCPMC4955732
OpenAlexW2462724854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.